Luc Djoussé1, Chisa Matsumoto, Andrew Petrone, Natalie L Weir, Michael Y Tsai, J Michael Gaziano. 1. Division of Aging, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St, 3rd floor, Boston, MA, 02120, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; The Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC) and Geriatric Research (GRECC), Boston Veterans Affairs Healthcare System, Boston, MA, USA.
Abstract
AIMS: We sought to test the hypothesis that plasma galectin 3 (Gal-3) is positively associated with the risk of heart failure (HF) in male subjects. METHODS AND RESULTS: While Gal-3 has been reported as prognostic factor in HF patients, limited data are available on the role of Gal-3 in the development of HF. We used a prospective nested-case control study (n = 462 cases and 462 controls) within the Physicians' Health Study for current analyses. For each case of HF, we randomly selected one control among subjects that were alive and free of HF at the time of index case occurrence and matched on age, race, and time of blood collection. Gal-3 was measured using ELISA and we used conditional logistic regression to compute adjusted odds ratios. Mean age at baseline was 58.3 y and median log-Gal-3 was 1.50 (IQR: 1.20-1.73) ng/ml. Cubic splines suggested a non-linear relation between Gal-3 and HF. Odds ratios (95% CI) for HF were 1.0 (ref), 0.89 (0.58-1.38), 1.08 (0.71-1.67), and 1.57 (1.03-2.39) across consecutive quartiles of Gal-3 after adjustment for body mass index, diabetes, atrial fibrillation, hypertension, C-reactive protein, alcohol, smoking, and exercise. The Gal-3-HF relation was seen for HF with and without antecedent coronary heart disease. CONCLUSIONS: Our data are consistent with a positive non-linear association between Gal-3 and HF risk in male subjects.
RCT Entities:
AIMS: We sought to test the hypothesis that plasma galectin 3 (Gal-3) is positively associated with the risk of heart failure (HF) in male subjects. METHODS AND RESULTS: While Gal-3 has been reported as prognostic factor in HF patients, limited data are available on the role of Gal-3 in the development of HF. We used a prospective nested-case control study (n = 462 cases and 462 controls) within the Physicians' Health Study for current analyses. For each case of HF, we randomly selected one control among subjects that were alive and free of HF at the time of index case occurrence and matched on age, race, and time of blood collection. Gal-3 was measured using ELISA and we used conditional logistic regression to compute adjusted odds ratios. Mean age at baseline was 58.3 y and median log-Gal-3 was 1.50 (IQR: 1.20-1.73) ng/ml. Cubic splines suggested a non-linear relation between Gal-3 and HF. Odds ratios (95% CI) for HF were 1.0 (ref), 0.89 (0.58-1.38), 1.08 (0.71-1.67), and 1.57 (1.03-2.39) across consecutive quartiles of Gal-3 after adjustment for body mass index, diabetes, atrial fibrillation, hypertension, C-reactive protein, alcohol, smoking, and exercise. The Gal-3-HF relation was seen for HF with and without antecedent coronary heart disease. CONCLUSIONS: Our data are consistent with a positive non-linear association between Gal-3 and HF risk in male subjects.
Authors: Roland R van Kimmenade; James L Januzzi; Patrick T Ellinor; Umesh C Sharma; Jaap A Bakker; Adrian F Low; Abelardo Martinez; Harry J Crijns; Calum A MacRae; Paul P Menheere; Yigal M Pinto Journal: J Am Coll Cardiol Date: 2006-08-28 Impact factor: 24.094
Authors: Lili Yu; Willem P T Ruifrok; Maxi Meissner; Eelke M Bos; Harry van Goor; Bahram Sanjabi; Pim van der Harst; Bertram Pitt; Irwin J Goldstein; Jasper A Koerts; Dirk J van Veldhuisen; Ruud A Bank; Wiek H van Gilst; Herman H W Silljé; Rudolf A de Boer Journal: Circ Heart Fail Date: 2012-12-10 Impact factor: 8.790
Authors: Umesh C Sharma; Saraswati Pokharel; Thomas J van Brakel; Jop H van Berlo; Jack P M Cleutjens; Blanche Schroen; Sabine André; Harry J G M Crijns; Hans-J Gabius; Jos Maessen; Yigal M Pinto Journal: Circulation Date: 2004-11-01 Impact factor: 29.690
Authors: Dirk J A Lok; Peter Van Der Meer; Pieta W Bruggink-André de la Porte; Erik Lipsic; Jan Van Wijngaarden; Hans L Hillege; Dirk J van Veldhuisen Journal: Clin Res Cardiol Date: 2010-02-04 Impact factor: 5.460
Authors: Lars Gullestad; Thor Ueland; John Kjekshus; Ståle H Nymo; Johannes Hulthe; Pieter Muntendam; John J V McMurray; John Wikstrand; Pål Aukrust Journal: Am Heart J Date: 2012-10-29 Impact factor: 4.749
Authors: Rudolf A de Boer; Dirk J A Lok; Tiny Jaarsma; Peter van der Meer; Adriaan A Voors; Hans L Hillege; Dirk J van Veldhuisen Journal: Ann Med Date: 2010-12-28 Impact factor: 4.709
Authors: Anahita Ghorbani; Vijeta Bhambhani; Robert H Christenson; Wouter C Meijers; Rudolf A de Boer; Daniel Levy; Martin G Larson; Jennifer E Ho Journal: J Am Coll Cardiol Date: 2018-12-25 Impact factor: 24.094
Authors: Oluwaseun E Fashanu; Faye L Norby; David Aguilar; Christie M Ballantyne; Ron C Hoogeveen; Lin Y Chen; Elsayed Z Soliman; Alvaro Alonso; Aaron R Folsom Journal: Am Heart J Date: 2017-07-08 Impact factor: 4.749
Authors: John W McEvoy; Yuan Chen; Marc K Halushka; Eric Christenson; Christie M Ballantyne; Roger S Blumenthal; Robert H Christenson; Elizabeth Selvin Journal: J Am Heart Assoc Date: 2016-05-13 Impact factor: 5.501
Authors: Salvatore Sciacchitano; Luca Lavra; Alessandra Morgante; Alessandra Ulivieri; Fiorenza Magi; Gian Paolo De Francesco; Carlo Bellotti; Leila B Salehi; Alberto Ricci Journal: Int J Mol Sci Date: 2018-01-26 Impact factor: 5.923